Though Affy's MicroRNA Genotyping Chips Don't Inspire Rival Offerings, Firms Say Market is Still Dynamic | GenomeWeb

Affymetrix's latest offering to researchers studying microRNA continues to stand alone in the marketplace.

A month after the firm launched catalog and custom genotyping arrays for the genome-wide evaluation of microRNA target sites, representatives for Agilent Technologies and Exiqon, two firms that compete against Affy in the miRNA array market, said they have no intention of launching a similar product. And while an Illumina representative said the firm plans to introduce arrays that include some similar content, a direct competitive offering is not planned.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.